Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AltaPointe's Behavioral Health Crisis Center Offers Innovative Approach to Fentanyl Addiction Treatment Using Ketamine in Combination with Buprenorphine


News provided by

AltaPointe Health

Nov 08, 2023, 19:00 ET

Share this article

Share toX

Share this article

Share toX

AltaPointe Health is an extensive behavioral and primary healthcare system in Alabama.
AltaPointe Health is an extensive behavioral and primary healthcare system in Alabama.

In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine. Leaders in the addiction medicine field are finding that ketamine, an anesthetic medicine often used to treat chronic pain or treatment-resistant depression, can greatly reduce opioid withdrawal symptoms and cravings.

MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

"We've treated about a dozen people using this new protocol, and it's been amazing what a difference it makes. We went from a process where it took about three days on average to switch somebody from fentanyl to buprenorphine, and now we are able to do it in about three hours," explained Dr. Luke Engeriser, Deputy Chief Medical Officer and Director of the Addiction Medicine Fellowship Program with AltaPointe Health.

"We went from a process where it took about three days on average to switch somebody from fentanyl to buprenorphine, and now we are able to do it in about three hours."

Post this

Because of fentanyl's high potency, it is much more complicated to treat than other opioids like heroin. Traditional treatments like Suboxone, if given too soon after opioid use, can actually make the withdrawal symptoms worse.

"Think about the worst flu that you've ever had and multiply it by ten. That's what people can go through during opioid withdrawal," explained Dr. Engeriser. "The withdrawal symptoms when someone is using opioids can be absolutely miserable and incredibly painful. It is so horribly uncomfortable that people may be desperately wanting to stop using the fentanyl, but they just can't, because it's so difficult to get through that process."

However, leaders in the addiction medicine field are finding that ketamine, an anesthetic medicine often used to treat chronic pain or treatment-resistant depression, can greatly reduce opioid withdrawal symptoms and cravings.

"If somebody comes in and they are having moderate opioid withdrawal, we give an injection of very low-dose ketamine. That, in itself, helps relieve a lot of the opioid withdrawal. And then 30 minutes later, we give that first dose of Suboxone," said Dr. Engeriser.

In the past, Dr. Engeriser explained that it could take a few days to help patients transition from fentanyl to buprenorphine due to the intense withdrawal symptoms. But with the use of ketamine, patients are able to return home in a matter of hours.

"When we treat these individuals at the BHCC, they can now walk out on the same day with a prescription for Suboxone and a follow-up appointment with our substance use treatment programs at AltaPointe Health," added Dr. Engeriser.

He hopes that this breakthrough can offer a more manageable path to recovery for those who are trapped in the cycle of opioid dependency.

"We are in the midst of a horrible opioid overdose epidemic, where people are dying every day. The use of ketamine in this way may be new, but I think there is a really important place for this in helping people transition to Suboxone quickly, safely, and comfortably," explained Dr. Engeriser.

ABOUT ALTAPOINTE

AltaPointe Health is an extensive behavioral and primary healthcare system in Alabama. AltaPointe operates two psychiatric hospitals, one behavioral health crisis center, and 24 outpatient clinics. A leader in behavioral health for more than 60 years, AltaPointe expanded its service array in 2018 to include primary care. Its clinicians provide more than 1.3 million services annually to more than 45,000 people across seven counties, including Baldwin, Clay, Coosa, Mobile, Talladega, Randolph and Washington.

Media Contact

April Douglas, Director of Public Relations, AltaPointe Health, (251) 544-4639, [email protected], www.AltaPointe.org

Twitter Facebook

SOURCE AltaPointe Health

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.